SCHEMBL19544302

SCHEMBL19544302

CCOC(=O)c1cc(-c2ccc(C(=O)N3CCCC3)cc2)n[nH]1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 6/20 0.63
▸ RAB9A P51151 5/20 0.62
▸ MAPT P10636 5/20 0.62
▸ NPC1 O15118 4/20 0.62
▸ L3MBTL1 Q9Y468 2/20 0.62
▸ ACR P10323 1/20 0.52
▸ KMT2A Q03164 2/20 0.50
▸ HPGDS O60760 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ HPGD P15428 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ CA12 O43570 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ TACR3 P29371 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19533645 0.80 ALDH1A1 (0.50) ALPLRAB9ANPC1L3MBTL1KMT2A
SCHEMBL2824803 0.78 ALPL (0.76) ALPLRAB9AMAPTNPC1L3MBTL1
SCHEMBL25168483 0.78 ALPL (0.76) ALPLRAB9AMAPTNPC1L3MBTL1
SCHEMBL1413959 0.78 ALPL (1.00) ALPLRAB9AMAPTNPC1L3MBTL1
SCHEMBL595997 0.78 ALPL (0.75) ALPLRAB9AMAPTNPC1L3MBTL1
SCHEMBL2888912 0.77 MAPT (1.00) ALPLRAB9AMAPTNPC1L3MBTL1
SCHEMBL4712555 0.76 ALPL (0.73) ALPLRAB9AMAPTNPC1L3MBTL1
SCHEMBL4692483 0.76 ALPL (0.72) ALPLRAB9AMAPTNPC1L3MBTL1
SCHEMBL10070273 0.76 ALPL (0.72) ALPLRAB9AMAPTNPC1L3MBTL1
SCHEMBL19544299 0.76 HPGD (0.46) RAB9ANPC1L3MBTL1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3246317-B1 BTK INHIBITOR HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) 2023-02-22 — — EP disclosed
US-10662174-B2 BTK inhibitor HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2020-05-26 — — US disclosed
EP-3246317-A1 BTK INHIBITOR Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) 2017-11-22 — — EP disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662174-B2 BTK inhibitor BTK, SYK, LYN ALPL 3689/4885RAB9A 1750/4885MAPT 418/4885
US-20170313683-A1 BTK INHIBITOR BTK, SYK, LYN ALPL 3689/4885RAB9A 1750/4885MAPT 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback